Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Sales and Divestitures (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Gains from Sales and Divestitures data on record, last reported at $980992.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 90.84% year-over-year to $980992.0; the TTM value through Sep 2025 reached $980992.0, up 90.84%, while the annual FY2024 figure was $967773.0, 43.24% up from the prior year.
  • Gains from Sales and Divestitures reached $980992.0 in Q3 2025 per COLL's latest filing, up from $895705.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $980992.0 in Q3 2025 and bottomed at $60990.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 5 years is $501551.3, with a median of $514050.0 recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 435.88% in 2023, then plummeted 76.16% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $444769.0 in 2021, then crashed by 71.65% to $126081.0 in 2022, then soared by 435.88% to $675647.0 in 2023, then skyrocketed by 43.24% to $967773.0 in 2024, then grew by 1.37% to $980992.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $980992.0 in Q3 2025, $895705.0 in Q2 2025, and $163423.0 in Q1 2025.